Disufenton sodium (NXY-059 Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutynitrone or PBN. It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial called SAINT-1 reported some efficacy in the acute treatment of ischemia injury due to stroke. However a 2006 attempt to repeat this trial indicated no significant activity.
This page contains content from the copyrighted Wikipedia article "Disufenton sodium"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
